Ultragenyx Pharmaceutical Inc.
NEWS
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Gene therapy is still very much cutting-edge with the potential to cure incurable genetic diseases. Here’s some recent news in the space.
The Rare Disease Company Coalition’s 10 founding members have brought 22 treatments to market and currently have more than 160 rare disease programs in the works.
Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
Wrapping up the month of July, there are three PDUFA dates on the U.S. Food and Drug Administration (FDA) calendar.
Crysvita is a drug developed by Ultragenyx Pharmaceutical and Tokyo-based Kyowa Kirin Co. Ltd., a specialty pharmaceutical company.
Ultragenyx Pharmaceutical Inc. today announced that Shalini Sharp, the company’s Chief Financial Officer, will present at the Piper Jaffray 31ST Annual Healthcare Conference on Wednesday, December 4, 2019 at 2:00 PM ET in New York, NY.
The companies included on this list are the top ten companies headquartered in Biotech Bay based on 2018 revenue.
Ultragenyx Pharmaceutical Inc. announced that Emil Kakkis, the company’s Chief Executive Officer and President will present at the Jefferies Gene Therapy/Editing Summit on Tuesday, October 8, 2019 at 9:45 AM ET in New York, NY.
JOBS
IN THE PRESS